Core Viewpoint - The approval of the inactivated vaccine for swine encephalitis by Jinhe Biotechnology's subsidiaries marks a significant advancement in the company's product offerings and enhances its position in the animal vaccine industry [1][2]. Group 1: Vaccine Development - Jinhe Biotechnology announced the approval of a new veterinary drug registration certificate for an inactivated vaccine against swine encephalitis, developed in collaboration with its subsidiaries and Beijing Huikang Yisheng Technology Co., Ltd [1]. - The inactivated vaccine is based on the A6-C strain isolated from infected pigs, providing better antigen matching and immunogenicity, and offering strong immune protection against currently circulating genotype I and III viruses [1]. Group 2: Industry Impact - The approval of the new vaccine is a result of the company's ongoing commitment to research and innovation, which will enhance its ability to provide comprehensive solutions to livestock customers [2]. - This development is expected to strengthen the company's market competitiveness and contribute positively to its sustainable development and research capabilities in the animal vaccine sector [2].

Core Logic - The company has strong R&D barriers and a rich pipeline of new products, with the non-epidemic vaccine having received clinical approval, which could become the largest growth engine in the next 3-5 years if progress is smooth [1] Industry Dynamics - The animal health sector is expected to maintain a volume increase but price decrease trend due to weak recovery in the breeding industry and profit compression, with overall gross margins declining amid intense competition and product homogenization [2] Product Development - The company is a leader in the foot-and-mouth disease vaccine market, transitioning its core product logic to the subunit non-epidemic vaccine, which has a broad market potential. The market size is expected to reach 1.75 billion yuan in the first year and 3.5 billion yuan in the second year post-launch. The subunit non-epidemic vaccine is set to enter clinical trials in July 2025, with potential revenue contributions starting from late 2027 to early 2028 [3] Marketing Strategy - The company focuses on "big products + big clients," providing comprehensive solutions and building a multi-layered marketing system. Online and overseas market expansions are showing initial success, with pet direct sales increasing over fourfold year-on-year in the first half of 2025. The company has registered sales of foot-and-mouth products in countries like Pakistan and Vietnam, with plans for deeper market penetration in Mongolia and Central Asia [4] Financial Forecast - The company expects overall revenue of 1.604 billion, 2.035 billion, and 2.521 billion yuan for 2025-2027, with year-on-year growth rates of 27.74%, 26.91%, and 23.85%. The net profit attributable to shareholders is projected to be 304 million, 398 million, and 491 million yuan, with growth rates of 178.44%, 31.04%, and 23.55%, corresponding to P/E ratios of 64, 49, and 39 times [5]

Group 1 - The company has changed its sponsor institution to Ping An Securities for the 2025 private placement of shares, with the original sponsor, Dongfang Securities, transferring its ongoing supervision responsibilities [2] - The company has signed a tripartite supervision agreement with China Minsheng Bank and Ping An Securities to regulate the management and use of raised funds, ensuring the protection of minority investors' rights [2][3] - The total amount raised from the private placement was approximately RMB 820 million, with a net amount of approximately RMB 802 million after deducting issuance costs [2] Group 2 - The tripartite supervision agreement stipulates that the raised funds will be stored in a dedicated account solely for specific projects, including production process efficiency improvements and energy-saving upgrades [3][4] - Ping An Securities will supervise the use of the raised funds and conduct semi-annual inspections of the fund's storage and usage [4][5] - The agreement includes provisions for notification of large withdrawals and compliance with anti-money laundering regulations [5][6] Group 3 - The company has received a new veterinary drug registration certificate for a new inactivated vaccine for swine encephalitis, developed in collaboration with several subsidiaries and partners [14] - The new vaccine is classified as a Class III veterinary drug and is designed to prevent swine encephalitis, with a recommended dosage of 2ml per pig [15][16] - The approval of this new vaccine is expected to enhance the company's product pipeline and strengthen its market position in the animal vaccine sector [20]

Core Viewpoint - Jinhe Biology (002688.SZ) announced the approval of a new veterinary drug, an inactivated vaccine for porcine encephalitis (A6-C strain), developed in collaboration with its subsidiaries and Beijing Huikang Yisheng Technology Co., Ltd. [1] Group 1 - The new veterinary drug was approved by the Ministry of Agriculture and Rural Affairs after review [1] - The vaccine is developed by Jinhe Biology's subsidiaries: Hangzhou Youben Animal Vaccine Co., Ltd., Jinhe Youben Biological Products Co., Ltd., and Hohhot Youben Vaccine Technology Co., Ltd. [1] - The approval includes the issuance of a "New Veterinary Drug Registration Certificate" [1]

Group 1 - The core point of the news is that Haili Biological experienced a stock price increase of 5.08%, reaching 6.41 CNY per share, with a total market capitalization of 4.203 billion CNY as of the report date [1] - Haili Biological, established on July 18, 1981, specializes in the research, production, and sales of animal vaccines, with its main business revenue composition being 71.34% from oral vaccines, 28.61% from IVD, and 0.05% from other sources [1] Group 2 - From the perspective of Haili Biological's top ten circulating shareholders, Guotai Fund's ETF, Guotai Zhongzheng Animal Husbandry ETF (159865), increased its holdings by 3.6987 million shares, totaling 10.2279 million shares, which represents 1.58% of the circulating shares [2] - The Guotai Zhongzheng Animal Husbandry ETF (159865) was established on March 1, 2021, with a current scale of 6.097 billion CNY and has achieved a year-to-date return of 11.41%, ranking 3417 out of 4189 in its category [2]

Core Viewpoint - The report from China Galaxy Securities emphasizes the dual opportunities in the pig farming industry, highlighting the importance of breeding sows and farming efficiency, with expectations of a price decline in 2026 but potential rebounds in between [1] Group 1: Pig Farming Industry - In December 2025, the pig price was 11.81 yuan/kg, down 27.4% from the end of 2024 [3] - The breeding profit for self-bred and purchased piglets was -130 yuan/head and -163 yuan/head respectively, indicating ongoing industry losses that may accelerate capacity reduction [3] - As of the end of October, the number of breeding sows was 39.9 million, a decrease of 1.1% month-on-month [3] - The annual average pig price is expected to decline year-on-year, with variations based on the performance of leading pig companies in cost optimization [3] - The report suggests focusing on leading companies with strong cost control, healthy financials, and reasonable valuations [3] Group 2: Agricultural Index Performance - In December, the agricultural index underperformed the CSI 300, with a decline of 0.95% compared to a 2.56% increase in the CSI 300 [2] - Among sub-industry indices, animal health showed a relative increase of 5.35%, while aquaculture and farming sectors declined by 2.01% and 3.81% respectively [2] Group 3: Pet Food Industry - In November, China's pet food export value was 838 million yuan, down 3.81% year-on-year, with export volume at 33,400 tons, up 11.23% [4] - The average export price was 25.08 yuan/kg, marking a year-on-year decrease of 13.51% [4] - Cumulatively from January to November, the export value was 9.196 billion yuan, down 4.18%, with a total export volume of 323,600 tons, up 6.96% [4] - The average export price for the same period was 28.42 yuan/kg, down 10.41% year-on-year [4]

Core Viewpoint - The stock of BioShares (600201) experienced a significant decline of 7.69% in a single trading day, with a turnover rate of 10.29% and a total transaction value of 1.799 billion yuan, indicating heightened market activity and investor concern [2]. Group 1: Stock Performance - The stock's price drop was attributed to a deviation of -8.23% from its daily limit, leading to its listing on the exchange's watchlist [2]. - The net selling by the Shanghai-Hong Kong Stock Connect amounted to 71.6877 million yuan, marking it as the largest selling entity for the day [2]. - The stock saw a net inflow of 46.8376 million yuan from major funds, with large orders contributing 35.8611 million yuan and big orders adding 10.9764 million yuan [2]. Group 2: Trading Data - The top five trading departments accounted for a total transaction value of 359 million yuan, with buying totaling 148 million yuan and selling reaching 211 million yuan, resulting in a net selling of 63.219 million yuan [2]. - The largest buying department was Guotai Junan Securities Headquarters, with a purchase amount of 41.4571 million yuan [3]. - The largest selling department was the Shanghai-Hong Kong Stock Connect, with a selling amount of 71.6877 million yuan [3]. Group 3: Financial Performance - For the first three quarters, the company reported a revenue of 1.042 billion yuan, reflecting a year-on-year growth of 7.38% [3]. - The net profit for the same period was 161 million yuan, showing a year-on-year decline of 4.85% [3]. Group 4: Margin Trading Data - As of December 23, the margin trading balance for the stock was 1.643 billion yuan, with a financing balance of 1.637 billion yuan and a securities lending balance of 6.0756 million yuan [2]. - Over the past five days, the financing balance increased by 70.1125 million yuan, representing a growth of 4.48% [2]. - The securities lending balance decreased by 432.9 thousand yuan, indicating a decline of 6.65% [2].

Group 1 - The animal vaccine sector experienced a decline of 0.47%, ranking among the top losers in concept sectors, with notable declines from companies like BioShares, Luo Niu Shan, and Tian Kang Bio [1] - Among the stocks in the animal vaccine sector, 10 stocks saw price increases, with Hengtong Co., Hai Zheng Pharmaceutical, and Hai Li Bio leading the gains at 3.67%, 0.69%, and 0.48% respectively [1] - The main capital outflow from the animal vaccine sector today was 87 million yuan, with 14 stocks experiencing net outflows, led by Luo Niu Shan with a net outflow of 95.06 million yuan [2] Group 2 - The top net inflow stocks in the animal vaccine sector included BioShares, Da Bei Nong, and Zhong Mu Co., with net inflows of 46.84 million yuan, 6.50 million yuan, and 3.83 million yuan respectively [2][3] - The capital outflow leaderboard for the animal vaccine sector included Luo Niu Shan, Hengtong Co., and Rui Pu Bio, with respective outflows of 95.06 million yuan, 11.49 million yuan, and 7.66 million yuan [2][3] - The trading activity showed that Luo Niu Shan had a turnover rate of 16.52%, while other companies like Hengtong Co. and Tian Kang Bio had turnover rates of 3.51% and 1.98% respectively [2][3]

Group 1 - The stock of the company "生物股份" reached a record trading volume of 1.491 billion yuan, marking the highest since its listing [2] - The latest stock price experienced a decline of 5.33%, with a turnover rate of 8.52% [2] - The trading volume for the previous trading day was 1.191 billion yuan [2]

Core Viewpoint - The major shareholder of the company, Inner Mongolia Jinyu Biological Holdings Co., Ltd., plans to increase its stake in the company by purchasing additional A-shares through the Shanghai Stock Exchange from December 24, 2025, to December 23, 2026, with an investment amount ranging from 50 million to 100 million yuan [1] Group 1 - The major shareholder currently holds 122 million shares, accounting for 11.00% of the company's total shares [1] - The planned increase in shareholding does not have a fixed price range, and the funds will come from self-owned and self-raised sources [1] - The major shareholder has committed not to reduce its holdings during the implementation period of the increase and for the statutory period after completion [1]